Real-time disaster intelligence, alerts, and response tools.
Tuesday, March 3, 2026
[ad_1] – Data reflect new insights and precision oncology advancements in portfolio and pipeline – – Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal […]
[ad_1] Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by 50% in […]
[ad_1] In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no new safety signals and no […]
[ad_1] First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival results from pivotal Phase 3 EV-303 trial show potential for […]
[ad_1] IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the U.S. Food and Drug Administration (FDA) approved expanded […]
